A survey of more than 600 people with myositis from the US, Korea, and Sweden identified 5 aspects of living with the disease that are most important to patients.
A new study found that people with scleroderma who have muscle weakness due to the accumulation of fibrous tissue in their muscles, are at risk for severe disease outcomes including death from heart disease.
A collaborative effort between Rheumatology and Oncology offers guidance to doctors treating patients for inflammatory arthritis caused by treatment with “immune checkpoint inhibitors”, a type of cancer therapy.
A study lead by Lisa Christopher-Stine, M.D., M.P.H. identified “Hiker’s Feet” as a new skin finding in some patients with inflammatory muscle disease (myositis).
Younger patients with a specific form of myositis associated with antibodies to a protein called HMGCR have a worse prognosis than older patients.
Medical record review of patients admitted to the Johns Hopkins Hospital over 20-years, revealed that pneumocystis jiroveci pneumonia infection is a rare but persistent risk for patients with rheumatic diseases.
Dr. Myma Albayda with the Johns Hopkins Arthritis Center highlights what’s involved in a joint injection.
In this issue of LEAP you can read about our precision approach to an increasingly common illness, gout, to a rare illness linked to Sjögren’s, and to cancer patients who are developing some autoimmune-mediated complications. And we are especially excited to share with you a tremendous breakthrough in understanding how rheumatoid arthritis begins.
The study provides new evidence that a bacterium known to cause chronic inflammatory gum infections also triggers the inflammatory autoimmune response characteristic of chronic, joint-destroying rheumatoid arthritis (RA). The new findings have important implications for prevention and treatment of RA.